Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Thromboelastography Better Reflects Hemostatic Abnormalities in Cirrhotics Compared With the International Normalized Ratio.

Hum J, Amador D, Shatzel JJ, Naugler WE, Ahn J, Zaman A, Chang M, Jou JH.

J Clin Gastroenterol. 2019 Nov 19. doi: 10.1097/MCG.0000000000001285. [Epub ahead of print]

PMID:
31764489
2.

Battle Royale: Systemic Versus Locoregional Therapy for Unresectable Hepatocellular Carcinoma.

Naugler WE.

AJR Am J Roentgenol. 2018 Jun;210(6):1366-1367. doi: 10.2214/AJR.17.19392. Epub 2018 Apr 18.

PMID:
29667887
3.

Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts.

Wang Y, Dorrell C, Naugler WE, Heskett M, Spellman P, Li B, Galivo F, Haft A, Wakefield L, Grompe M.

Mol Ther. 2018 May 2;26(5):1327-1342. doi: 10.1016/j.ymthe.2018.02.014. Epub 2018 Feb 21.

4.

Ganja, No Barrier for Liver Transplantation?

Naugler WE, Orloff SL.

Transplantation. 2018 May;102(5):720-722. doi: 10.1097/TP.0000000000002134. No abstract available.

PMID:
29461440
5.

Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.

Nabavizadeh N, Waller JG, Fain R 3rd, Chen Y, Degnin CR, Elliott DA, Mullins BT, Patel IA, Dyer BA, Fakhoury K, Naugler WE, Farsad K, Tanyi JA, Fuss M, Thomas CR Jr, Hung AY.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):577-585. doi: 10.1016/j.ijrobp.2017.11.030. Epub 2017 Nov 27.

PMID:
29413273
6.

Ectopic expansion of engineered human liver tissue seeds using mature cell populations.

Hickey RD, Naugler WE.

Hepatology. 2018 Jun;67(6):2465-2467. doi: 10.1002/hep.29718. Epub 2018 Apr 19. No abstract available.

PMID:
29222915
7.

Symptom Distress in Patients With Hepatocellular Carcinoma Toward the End of Life.

Hansen L, Dieckmann NF, Kolbeck KJ, Naugler WE, Chang MF.

Oncol Nurs Forum. 2017 Nov 1;44(6):665-673. doi: 10.1188/17.ONF.665-673.

PMID:
29052660
8.

Marked Decrease in Urgent Listing for Liver Transplantation Over Time: Evolution of Characteristics and Outcomes of Status-1 Liver Transplantation.

Wong LL, Truong HP, Seto T, Lacar L, Naugler WE.

Transplantation. 2018 Jan;102(1):e18-e25. doi: 10.1097/TP.0000000000001967.

PMID:
28968354
9.

Higher Mortality and Survival Benefit in Obese Patients Awaiting Liver Transplantation.

Schlansky B, Naugler WE, Orloff SL, Enestvedt CK.

Transplantation. 2016 Dec;100(12):2648-2655.

PMID:
27575690
10.

Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers.

Naugler WE, Tarlow BD, Fedorov LM, Taylor M, Pelz C, Li B, Darnell J, Grompe M.

Gastroenterology. 2015 Sep;149(3):728-40.e15. doi: 10.1053/j.gastro.2015.05.043. Epub 2015 May 29.

11.

Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes.

Tarlow BD, Pelz C, Naugler WE, Wakefield L, Wilson EM, Finegold MJ, Grompe M.

Cell Stem Cell. 2014 Nov 6;15(5):605-18. doi: 10.1016/j.stem.2014.09.008. Epub 2014 Oct 9.

12.

Malignant infiltration of the liver presenting as acute liver failure.

Rich NE, Sanders C, Hughes RS, Fontana RJ, Stravitz RT, Fix O, Han SH, Naugler WE, Zaman A, Lee WM.

Clin Gastroenterol Hepatol. 2015 May;13(5):1025-8. doi: 10.1016/j.cgh.2014.09.040. Epub 2014 Sep 30.

13.

Building the multidisciplinary team for management of patients with hepatocellular carcinoma.

Naugler WE, Alsina AE, Frenette CT, Rossaro L, Sellers MT.

Clin Gastroenterol Hepatol. 2015 May;13(5):827-35. doi: 10.1016/j.cgh.2014.03.038. Epub 2014 Jun 5. Review.

14.

Bile acid flux is necessary for normal liver regeneration.

Naugler WE.

PLoS One. 2014 May 19;9(5):e97426. doi: 10.1371/journal.pone.0097426. eCollection 2014.

15.

Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.

Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE.

Liver Transpl. 2014 Sep;20(9):1045-56. doi: 10.1002/lt.23917. Epub 2014 Aug 4.

16.

Who should undergo liver transplantation for hepatocellular carcinoma? Ablate, wait … and see!

Naugler WE, Schlansky B, Orloff SL.

Hepat Oncol. 2014 Apr;1(2):165-168. doi: 10.2217/hep.14.2. Epub 2014 Mar 20. No abstract available.

17.

Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group.

Mellinger JL, Rossaro L, Naugler WE, Nadig SN, Appelman H, Lee WM, Fontana RJ.

Dig Dis Sci. 2014 Jul;59(7):1630-7. doi: 10.1007/s10620-014-3029-2. Epub 2014 Jan 25. Review.

18.

Mice with chimeric livers are an improved model for human lipoprotein metabolism.

Ellis EC, Naugler WE, Parini P, Mörk LM, Jorns C, Zemack H, Sandblom AL, Björkhem I, Ericzon BG, Wilson EM, Strom SC, Grompe M.

PLoS One. 2013 Nov 4;8(11):e78550. doi: 10.1371/journal.pone.0078550. eCollection 2013. Erratum in: PLoS One. 2014;9(7):e103870. Nauglers, Scott [corrected to Naugler, Willscott Edward].

19.

Portal Biliopathy Causing Recurrent Biliary Obstruction and Hemobilia.

Schlansky B, Kaufman JA, Bakis G, Naugler WE.

ACG Case Rep J. 2013 Oct 8;1(1):44-6. doi: 10.14309/crj.2013.16. eCollection 2013 Oct.

20.

Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis.

Wong LL, Naugler WE, Schwartz J, Scott DL, Bhattacharya R, Reyes J, Orloff SL.

Clin Transplant. 2013 Jan-Feb;27(1):E72-9. doi: 10.1111/ctr.12056. Epub 2012 Dec 30.

PMID:
23278701
21.

Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma.

Naugler WE, Sonnenberg A.

Liver Transpl. 2010 Oct;16(10):1186-94. doi: 10.1002/lt.22129.

22.

Models of influence in chronic liver disease.

Sonnenberg A, Naugler WE.

Liver Int. 2010 May;30(5):718-24. doi: 10.1111/j.1478-3231.2009.02196.x. Epub 2009 Dec 22.

PMID:
20040051
23.

Hepatocellular carcinoma.

Naugler WE, Schwartz JM.

Dis Mon. 2008 Jul;54(7):432-44. doi: 10.1016/j.disamonth.2008.03.005. No abstract available.

PMID:
18570913
24.

NF-kappaB and cancer-identifying targets and mechanisms.

Naugler WE, Karin M.

Curr Opin Genet Dev. 2008 Feb;18(1):19-26. doi: 10.1016/j.gde.2008.01.020. Epub 2008 Apr 24. Review.

25.

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.

Naugler WE, Karin M.

Trends Mol Med. 2008 Mar;14(3):109-19. doi: 10.1016/j.molmed.2007.12.007. Epub 2008 Feb 7. Review.

PMID:
18261959
26.

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M.

Science. 2007 Jul 6;317(5834):121-4. Erratum in: Science. 2009 Dec 4;326(5958):1346.

27.

Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, Holte S, Naugler WE, Pawluk DM, Li CC, Frenkel LM.

J Clin Microbiol. 2004 Aug;42(8):3670-4.

28.

Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.

Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, Holte SE, De Vange SM, Pawluk DM, Melvin AJ, Lewis PF, Heath LM, Beck IA, Mahalanabis M, Naugler WE, Tobin NH, Mullins JI.

J Virol. 2003 May;77(10):5721-30.

29.

T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.

Naugler WE, Yong FH, Carey VJ, Dragavon JA, Coombs RW, Frenkel LM.

J Infect Dis. 2002 Feb 15;185(4):448-55. Epub 2002 Jan 31.

PMID:
11865396
30.

The use of intravenous colchicine and desacetylmethyl colchicine (colcemide) in vertigo, acute sensitivity states, and painful lymphadenopathy.

NAUGLER WE, KUZELL WC, SCHAFFARZICK RW.

Stanford Med Bull. 1957 May;15(2):97-102. No abstract available.

PMID:
13433079
31.

Phenylbutazone; effects of its administration for prolonged periods.

KUZELL WC, SCHAFFARZICK RW, NAUGLER WE, CHAMPLIN BM.

N Engl J Med. 1957 Feb 28;256(9):388-92. No abstract available.

PMID:
13419008
32.

[Administration of phenylbutazone from 12 to 54 months in 100 cases of chronic inflammatory rheumatism].

KUZELL W, SCHAFFARZICK RW, NAUGLER WE, CHAMPLIN B.

Rhumatologie. 1956 Sep-Oct;(5):222. French. No abstract available.

PMID:
13421361
33.

Some observations on 520 gouty patients.

KUZELL WC, SCHAFFARZICK RW, NAUGLER WE, KOETS P, MANKLE EA, BROWN B, CHAMPLIN B.

J Chronic Dis. 1955 Dec;2(6):645-69. No abstract available.

PMID:
13271515
34.

The effect of intravenous demecolcine (colcemid) on acute gout.

KUZELL WC, SCHAFFARZICK RW, NAUGLER WE.

AMA Arch Intern Med. 1955 Aug;96(2):153-6. No abstract available.

PMID:
14397874
35.

Variation of blood glutathione during neutropenia; case report.

KUZELL WC, KOETS P, SCHAFFARZICK RW, NAUGLER WE.

Stanford Med Bull. 1955 May;13(2):284-9. No abstract available.

PMID:
14386181
36.

Phenylbutazone (butazolidin) in gout.

KUZELL WC, SCHAFFARZICK RW, NAUGLER WE, GAUDIN G, MANKLE EA, BROWN B.

Am J Med. 1954 Feb;16(2):212-7. No abstract available.

PMID:
13124352
37.

The effect of colchicine on visible alimentary lipemia.

NAUGLER WE, BROWN BJ.

Stanford Med Bull. 1953 Nov;11(4):274-5. No abstract available.

PMID:
13122308
38.

Phenylbutazone; further clinical evaluation.

KUZELL WC, SCHAFFARZICK RW, NAUGLER WE, GAUDIN G, MANKLE EA.

AMA Arch Intern Med. 1953 Nov;92(5):646-61. No abstract available.

PMID:
13091481
39.

Clinical toxicity of phenylbutazone (Butazolidin).

KUZELL WC, SHAFFARZICK RW, NAUGLER WE, GAUDIN G, MANKLE EA.

Stanford Med Bull. 1953 Aug;11(3):194. No abstract available.

PMID:
13102040
40.

The effect of phenylbutazone (Butazolidin) and cortisone acetate on gold toxicity.

GRETHER I, NAUGLER WE, KUZELL WC.

Stanford Med Bull. 1952 Nov;10(4):322-3. No abstract available.

PMID:
13015304

Supplemental Content

Loading ...
Support Center